Hailong Liu1,2, Youliang Sun3, Jenny A O'Brien4,5, Janusz Franco-Barraza5, Xueling Qi1, Hongyu Yuan6, Wei Jin7, Junping Zhang2, Chunyu Gu2, Zhenyu Zhao1, Chunjiang Yu2, Shiyu Feng1, Xinguang Yu1. 1. Department of Neurosurgery, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China. 2. Sanbo Brain Hospital, Capital Medical University, Beijing, China. 3. School of Basic Medical Science, Capital Medical University, Beijing, China. 4. Department of Internal Medicine, Temple University Health System, Philadelphia, Pennsylvania, USA. 5. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. 6. State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Science Cancer Hospital/National Cancer Center, Beijing, China. 7. Department of Pathology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Abstract
BACKGROUND: Medulloblastoma (MB) with metastases at diagnosis and recurrence correlates with poor prognosis. Unfortunately, the molecular mechanism underlying metastases growth has received less attention than primary therapy-naïve MB. Though astrocytes have been frequently detected in brain tumors, their roles in regulating the stemness properties of MB stem-like cells (MBSCs) in disseminated lesions remain elusive. METHODS: Effects of tumor-associated astrocyte (TAA)-secreted chemokine C-C ligand 2 (CCL2) on MBSC self-renewal was determined by immunostaining analysis. Necroptosis of TAA was examined by measuring necrosome activity. Alterations in Notch signaling were examined after inhibition of CCL2. Progression of MBSC-derived tumors was evaluated after pharmaceutical blockage of necroptosis. RESULTS: TAA, as the essential components of disseminated tumor, produced high levels of CCL2 to shape the inflammation microenvironment, which stimulated the enrichment of MBSCs in disseminated MB. In particular, CCL2 played a pivotal role in maintaining stem-like properties via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3)-mediated activation of Notch signaling. Loss of CCL2/C-C chemokine receptor 2 (CCR2) function repressed the JAK2/STAT3-Notch pathway and impaired MBSC proliferation, leading to a dramatic reduction of stemness, tumorigenicity, and metastasizing capability. Furthermore, necroptosis-induced CCL2 release depended on activation of receptor-interacting protein 1 (RIP1)/RIP3/mixed lineage kinase domain-like pseudokinase (MLKL) in TAA, which promoted the oncogenic phenotype. Blockade of necroptosis resulted in CCL2 deprivation and compromised MBSC self-proliferation, indicating MBSCs outsourced CCL2 from necroptotic TAA. Finally, CCL2 was upregulated in high-risk stages of MB, further supporting its value as a prognostic indicator. CONCLUSION: These findings highlighted the critical role of CCL2/CCR2 in Notch signaling activation in MBSCs and revealed a necroptosis-associated glial cytokine microenvironment driving stemness maintenance in disseminations.Key Points1. TAA-derived CCL2 promoted stemness in disseminated MBSCs through Notch signaling activation via the JAK2/STAT3 pathway.2. TAA released CCL2 in a RIP1/RIP3/MLKL-dependent manner leading to necroptosis.
BACKGROUND: Medulloblastoma (MB) with metastases at diagnosis and recurrence correlates with poor prognosis. Unfortunately, the molecular mechanism underlying metastases growth has received less attention than primary therapy-naïve MB. Though astrocytes have been frequently detected in brain tumors, their roles in regulating the stemness properties of MB stem-like cells (MBSCs) in disseminated lesions remain elusive. METHODS: Effects of tumor-associated astrocyte (TAA)-secreted chemokine C-C ligand 2 (CCL2) on MBSC self-renewal was determined by immunostaining analysis. Necroptosis of TAA was examined by measuring necrosome activity. Alterations in Notch signaling were examined after inhibition of CCL2. Progression of MBSC-derived tumors was evaluated after pharmaceutical blockage of necroptosis. RESULTS: TAA, as the essential components of disseminated tumor, produced high levels of CCL2 to shape the inflammation microenvironment, which stimulated the enrichment of MBSCs in disseminated MB. In particular, CCL2 played a pivotal role in maintaining stem-like properties via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3)-mediated activation of Notch signaling. Loss of CCL2/C-C chemokine receptor 2 (CCR2) function repressed the JAK2/STAT3-Notch pathway and impaired MBSC proliferation, leading to a dramatic reduction of stemness, tumorigenicity, and metastasizing capability. Furthermore, necroptosis-induced CCL2 release depended on activation of receptor-interacting protein 1 (RIP1)/RIP3/mixed lineage kinase domain-like pseudokinase (MLKL) in TAA, which promoted the oncogenic phenotype. Blockade of necroptosis resulted in CCL2 deprivation and compromised MBSC self-proliferation, indicating MBSCs outsourced CCL2 from necroptotic TAA. Finally, CCL2 was upregulated in high-risk stages of MB, further supporting its value as a prognostic indicator. CONCLUSION: These findings highlighted the critical role of CCL2/CCR2 in Notch signaling activation in MBSCs and revealed a necroptosis-associated glial cytokine microenvironment driving stemness maintenance in disseminations.Key Points1. TAA-derived CCL2 promoted stemness in disseminated MBSCs through Notch signaling activation via the JAK2/STAT3 pathway.2. TAA released CCL2 in a RIP1/RIP3/MLKL-dependent manner leading to necroptosis.
Authors: Livia Garzia; Noriyuki Kijima; A Sorana Morrissy; Pasqualino De Antonellis; Ana Guerreiro-Stucklin; Borja L Holgado; Xiaochong Wu; Xin Wang; Michael Parsons; Kory Zayne; Alex Manno; Claudia Kuzan-Fischer; Carolina Nor; Laura K Donovan; Jessica Liu; Lei Qin; Alexandra Garancher; Kun-Wei Liu; Sheila Mansouri; Betty Luu; Yuan Yao Thompson; Vijay Ramaswamy; John Peacock; Hamza Farooq; Patryk Skowron; David J H Shih; Angela Li; Sherine Ensan; Clinton S Robbins; Myron Cybulsky; Siddhartha Mitra; Yussanne Ma; Richard Moore; Andy Mungall; Yoon-Jae Cho; William A Weiss; Jennifer A Chan; Cynthia E Hawkins; Maura Massimino; Nada Jabado; Michal Zapotocky; David Sumerauer; Eric Bouffet; Peter Dirks; Uri Tabori; Poul H B Sorensen; Priscilla K Brastianos; Kenneth Aldape; Steven J M Jones; Marco A Marra; James R Woodgett; Robert J Wechsler-Reya; Daniel W Fults; Michael D Taylor Journal: Cell Date: 2018-05-31 Impact factor: 41.582
Authors: Katie B Grausam; Samuel D R Dooyema; Laure Bihannic; Hasitha Premathilake; A Sorana Morrissy; Antoine Forget; Amanda M Schaefer; Justin H Gundelach; Slobodan Macura; Diane M Maher; Xin Wang; Alex H Heglin; Xijin Ge; Erliang Zeng; Stephanie Puget; Indra Chandrasekar; Kameswaran Surendran; Richard J Bram; Ulrich Schüller; Michael D Talyor; Olivier Ayrault; Haotian Zhao Journal: Cancer Res Date: 2017-05-10 Impact factor: 12.701
Authors: Alan L Chang; Jason Miska; Derek A Wainwright; Mahua Dey; Claudia V Rivetta; Dou Yu; Deepak Kanojia; Katarzyna C Pituch; Jian Qiao; Peter Pytel; Yu Han; Meijing Wu; Lingjiao Zhang; Craig M Horbinski; Atique U Ahmed; Maciej S Lesniak Journal: Cancer Res Date: 2016-08-16 Impact factor: 12.701
Authors: Anwar Zaiter; Zahraa F Audi; Fatima Shawraba; Zahraa Saker; Hisham F Bahmad; Rami H Nabha; Hayat Harati; Sanaa M Nabha Journal: Mol Biol Rep Date: 2022-06-18 Impact factor: 2.316
Authors: Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares Journal: Curr Treat Options Oncol Date: 2021-07-30